New Survey Reveals Financial Strain on Insulin Users Amid Rising Costs and Advocacy Efforts

Rising Financial Strain for Insulin Users

A recent survey conducted by the American Diabetes Association (ADA) brings to light the troubling reality for those who depend on insulin. As the cost of this essential medication continues to climb, the economic burden on patients is becoming unsustainable. According to the findings, an alarming 40% of insulin users report spending more than $150 every month for their medication, while a staggering 72% spend over $35. These figures point to a widespread issue that affects many individuals and families across the United States.

Among respondents with insulin dependency, the survey also highlights that cost challenges are especially severe for middle-class Americans. For instance, 44% of those earning between $50,000 and $75,000 annually and 55% making between $75,000 and $99,000 say they pay more than $150 for their insulin every month. This demonstrates that insulin pricing is not just a healthcare problem, but also a socioeconomic one that impacts the overall wellbeing of individuals who require this vital drug.

The financial strain on patients is compounded by a growing necessity for compromise due to healthcare costs. The survey reports that roughly one-third of participants have had to forgo groceries to accommodate medical expenses, while nearly 25% have delayed or skipped necessary medical appointments. This reality underscores the significant sacrifices many insulin-dependent individuals face.

Despite some legislative efforts, such as initiatives in Medicare and implementations across 29 states and Washington, D.C., individuals with private or employer-sponsored health insurance, as well as the uninsured, are burdened by costs that can soar above $400 monthly in many cases. This has amplified calls for reform, including bipartisan efforts from Senators Jeanne Shaheen, Susan Collins, Raphael Warnock, and John Kennedy, who introduced the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026.

The INSULIN Act aims to establish a monthly cap of $35 for out-of-pocket insulin costs for those with private or employer-sponsored health plans. Such legislation has gained widespread support, with 76% of survey respondents advocating for a limit on cost-sharing across political affiliations.

Lisa Murdock, Chief Advocacy Officer for the ADA, emphasizes the urgency of addressing insulin pricing by stating, “We have made significant progress in reducing insulin costs in this country, but we still have a long way to go. Half of all insulin-dependent individuals are still resorting to rationing their medication, and three-quarters are paying more than $35 a month. It is unacceptable for anyone to miss a dose of this lifesaving drug due to financial constraints.”

The survey, conducted in June 2026 with a sample of 1,527 U.S. adults, reveals important insights into the healthcare landscape affecting diabetic patients. Data has been weighted to ensure accuracy by factoring in variables such as age, gender, race/ethnicity, education, and geographic region, resulting in a margin of error of approximately ±2.5 percentage points at a 95% confidence level.

The ADA, which has championed diabetes awareness and research for 85 years, continues to push for urgent reform. With over 155 million Americans living with diabetes or prediabetes, the organization aims to use this data to advocate for policies that help patients afford essential medications like insulin. For those wanting to get involved or learn more about advocacy efforts, the ADA offers resources through their official website and various social media platforms, including Facebook and LinkedIn.

As the conversation around insulin pricing evolves, the need for collective action and change remains critical. It is clear that there are lives at stake, and effective policies must emerge to ensure insulin is accessible to all who need it.